Allergan has long dominated the anti-wrinkle arena with its Botox product, but it appears cosmo-pharma giant Johnson & Johnson is preparing to offer serious competition, with the development of its latest drug.
California-based Allergan Inc has had its in-vitro, cell-based assay for testing the stability and potency of Botox and Botox cosmetic, approved by the FDA.
The British Union for the Abolition of Vivisection (BUAV) has branded botox tests on animals as ‘appalling cruelty’ and highlighted a loophole in the law allowing botox to be tested for cosmetic purposes.
The FDA has agreed to evaluate an anti-wrinkle injection treatment
from France-based pharmaceutical company Ipsen which if approved
would provide a rival for Allergan's Botox.
Mentor Corporation says it has begun a Phase 2 dose-finding study
for its botulinum toxin type A product focused on cosmetic
indications in the US - a move that aims to tap into the still
growing market for non-surgical anti-aging...
If emerging semi-permanent beauty solutions, such as Allergan's
Botox anti-sweat treatment using botulinum toxin type A, prove
effective, they could have an impact on skin care and deodorant
sales in the long term.
Mentor, a global supplier of medical products, says it has
initiated an initial study of its proprietary botulinum toxin type
A product, focused on the cosmetic applications for the US market.
The company says that the study aims...
Irish neuroscience based biopharmaceuticals company Elan has sold
its botulinum toxin type B product Myobloc/Neurobloc to Solstice
Neurosciences for up to €15 million.